Table 3

Perioperative surgical outcomes for patients who received or did not receive a vitamin K antagonist

StudyAdmission INR, mean ± SD (range)Time to surgery, mean ± SD (range), hLength of stay, mean ± SD (range), dDeep vein thrombosis, no. of patientsPulmonary embolism, no. of patientsPostoperative venous thromboembolism, no. of patients
Before protocolAfter protocolBefore protocolAfter protocolControlBefore protocolAfter protocolControlBefore protocolAfter protocolControlBefore protocolAfter protocolControlBefore protocolAfter protocolControl
Schuetze et al., (29) 2019NR10.0 (4.3–23.8)8.2 (1.2–23.9)NRNRNRNRNRNRNRNR
Mattisson et al., (15) 20182.5 (0.6)16.0 (4.8)14.0 (5.6)4.9 (2.6)4.9 (2.6)000000
Moores et al., (29) 20192.6 (0.9)2.5 (1.0)70.4 (61.9)46.0 (38.0)17.3 (14.2)22.4 (39.7)NRNRNRNRNRNR
Ng et al., (28) 20193.1 (1.5)32.5 (23.2)11 (2–62)*101
Diament et al., (21) 20152.5 (1.5–4.4)53.7 (1.7–128.0)37.6 (14.7–71.8)28.4 (5.0–286.4)16.7 (2.0–65.0)15.8 (8.0–44.0)14.1 (2.0–67.0)000
Ahmed et al., (23) 20143.4 (3.6)3.3 (2.6)74.7 (43.7)36.9 (12.6)24.4 (14.8)22.1 (14.1)NRNRNRNRNRNR
Buecking et al., (24) 2014
 PCCs2.0 (0.7)2.3 (0.6)28.0 (15.0)21.0 (10.0)NRNR000000
 Vitamin K ± PCCs2.1 (0.7)27.0 (14.0)16.0 (12.0)15.0 (6.0)13.0 (6.0)010203
Tal et al., (30) 20132.7 (0.7)2.4 (0.7)122.4 (58.1)63.4 (26.9)16.6 (19.9)13.2 (4.9)9.4 (1.9)7.3 (2.4)NRNRNRNRNRNRNRNRNR
Ashouri et al., (22) 2011NRNR74.7 (43.7)36.9 (12.6)24.4 (14.8)22.1 (14.1)NRNRNRNRNRNR
Vitale et al., (31) 20111.9 (0.7)2.6 (1.1)163.2 (45.6)67.2 (31.2)NRNR020103
Bhatia et al., (25) 20102.9 (1.5–6.5)2.5 (1.9–7.1)9138NRNRNRNRNRNRNRNR
Weighted total, no. (%)2.62.671.435.519.619.215.311.50 (0.0)3 (0.9)1 (0.2)0 (0.0)1 (0.3)2 (0.5)0 (0.0)4 (1.3)3 (0.7)
  • INR = International Normalized Ratio; NR = not recorded; PCC = prothrombin complex concentrate; SD = standard deviation.

  • * Reported as median and range (not included in weighted total calculation).

  • Not included in total calculations as it was a subgroup analysis.